Certara (CERT) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
26 Feb, 2026Executive summary
FY 2025 revenue reached $418.8M, up 9% year-over-year, with adjusted EBITDA of $134.5M, up 10%.
Q4 2025 revenue was $103.6M, a 3% increase year-over-year; adjusted EBITDA was $32.5M, down 3%.
Net loss for Q4 2025 was $5.9M, compared to net income of $6.6M in Q4 2024.
Jon Resnick was appointed CEO effective January 1, 2026, bringing over 30 years of experience.
Strategic priorities include operational improvements, AI integration, and customer-centric strategies.
Financial highlights
FY 2025 GAAP revenue grew 9% year-over-year to $418.8M; Q4 2025 revenue was $103.6M, up 3%.
FY 2025 adjusted EBITDA was $134.5M (32% margin), up 10% year-over-year.
Q4 software revenue grew 10% year-over-year to $46.4M; full-year software revenue was $183.3M, up 18%.
Q4 services revenue was $57.3M, down 1% year-over-year; full-year services revenue was $235.6M, up 3%.
Repurchased 3.3M shares for $43M in 2025; ended year with $189.4M in cash.
Outlook and guidance
FY 2026 revenue growth expected in the range of 0–4%.
Adjusted EBITDA margin projected at 30–32% for FY 2026, with margin lower in H1 and improving in H2.
Adjusted diluted EPS for FY 2026 expected between $0.44 and $0.48.
Fully diluted shares forecasted at 160–162 million; effective tax rate modeled at 30%.
Q1 2026 expected at the low end of revenue range due to tough comparison; acceleration anticipated in later quarters.
Latest events from Certara
- AI-driven product launches and disciplined cost control set the stage for cautious 2026 growth.CERT
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - 2026 guidance reflects stable markets, strong biosimulation growth, and operational transformation.CERT
Leerink Global Healthcare Conference 20269 Mar 2026 - Operational rigor, AI innovation, and cloud migration drive growth amid evolving regulatory and market dynamics.CERT
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Strong biotech demand, AI-driven innovation, and cloud adoption fuel growth amid regulatory shifts.CERT
Stephens Annual Investment Conference3 Feb 2026 - Q2 revenue up 3% to $93.3M, net loss $12.6M, guidance reiterated at $385M–$400M.CERT
Q2 20242 Feb 2026 - Biosimulation and AI adoption accelerate, supported by acquisitions and a unified cloud platform.CERT
Jefferies Global Healthcare Conference1 Feb 2026 - AI-driven software growth and stable services underpin a broad biosimulation market opportunity.CERT
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - AI-driven biosimulation and cloud integration fuel growth and efficiency across drug development.CERT
The Baird 2024 Global Healthcare Conference21 Jan 2026 - Q3 2024 revenue up 11%, net loss narrows, and biosimulation drives growth.CERT
Q3 202416 Jan 2026